| Revenue growth | 16.6% YoY in Q4; 12.2% in FY26. |
|---|---|
| Margins | Targeting 27-28% EBITDA margins despite infra investments. |
| Demand visibility | Strong volume growth (8.2% in Q4) and rising samples per patient. |
| Management confidence | Confident in sustaining early to mid-teens growth for FY27. |
Growth
Q4 revenue grew 16.6% to ₹703cr; FY26 revenue grew 12.2% to ₹2,763cr. EBITDA margin normalized at 28.3%.
Outlook
FY27 revenue guidance of early to mid-teens (13-15%). Capex planned at ₹100-120cr for labs and radiology.
Risks
Potential supply chain impacts from Middle East conflict affecting reagent imports; wage costs from new Labour Code.
Earnings Call filed with NSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,952.30
- Market cap
- ₹32,769 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 60.5×Sector 57.8×
- Promoter holding
- 53.19%-0.02% QoQ
- FII holding
- 17.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Dr. Lal Pathlabs Acquisition
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Lal Pathlabs Employee Stock Options
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
- Value
- ₹1.42 Cr
Dr. Lal Pathlabs Acquisition Worth ₹168 Cr
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
- Value
- ₹168.0 Cr
Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
- Value
- ₹199.5 Cr